Absence of the calcium-binding protein, S100A1, confers pulmonary hypertension in mice associated with endothelial dysfunction and apoptosis
Open Access
- 13 November 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 105 (1), 8-19
- https://doi.org/10.1093/cvr/cvu241
Abstract
S100A1, a 10-kDa, Ca2+-binding protein, is expressed in endothelial cells (ECs) and binds eNOS. Its absence is associated with impaired production of nitric oxide (NO) and mild systemic hypertension. As endothelial dysfunction contributes to clinical and experimental pulmonary hypertension (PH), we investigated the impact of deleting S100A1 in mice, on pulmonary haemodynamics, endothelial function, NO production, associated signalling pathways, and apoptosis. Compared with wild-type (WT), S100A1-knock-out mice (KO) exhibited increased right ventricular (RV) weight/body weight ratio and elevated RV pressure in the absence of altered left ventricular filling pressures, accompanied by increase in wall thickness of muscularized pulmonary arteries and a reduction in microvascular perfusion. In isolated lung preparations, KO revealed reduced basal NO, blunted dose-responsiveness to acetylcholine, and augmented basal and angiotensin (AII)-induced pulmonary vascular resistance (R0) compared with WT. Pre-treatment of KO lungs with S100A1 attenuated the AII-induced increase in pulmonary arterial pressure and R0. S100A1-induced phosphorylation of eNOS, Akt, and ERK1/2 is attenuated in pulmonary EC of KO compared with WT. Basal and TNF-α-induced EC apoptosis is greater in KO vs. WT, and cell survival is enhanced by S100A1 treatment. Our data demonstrate that the absence of S100A1 results in PH by disruption of its normal capacity to (i) enhance pulmonary EC function by induction of eNOS activity and NO levels via Akt/ERK1/2 pathways and (ii) promote EC survival. The ability of exogenously administered S100A1 to rescue this phenotype makes it an attractive therapeutic target in the treatment of PH.Keywords
This publication has 47 references indexed in Scilit:
- Pulmonary arterial hypertensionOrphanet Journal of Rare Diseases, 2013
- Critical Role for the Advanced Glycation End‐Products Receptor in Pulmonary Arterial Hypertension EtiologyJournal of the American Heart Association, 2013
- Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to femalesRespiratory Research, 2011
- S100B Interaction With the Receptor for Advanced Glycation End Products (RAGE)Circulation Research, 2010
- S100A1 in cardiovascular health and disease: Closing the gap between basic science and clinical therapyJournal of Molecular and Cellular Cardiology, 2009
- The angiopietin-1–Tie2 pathway prevents rather than promotes pulmonary arterial hypertension in transgenic miceThe Journal of Experimental Medicine, 2009
- Expression of S100A6 in Cardiac Myocytes Limits Apoptosis Induced by Tumor Necrosis Factor-αPublished by Elsevier BV ,2008
- Inhibition of MEK/ERK1/2 signalling alters endothelial nitric oxide synthase activity in an agonist-dependent mannerBiochemical Journal, 2006
- Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertensionThe FASEB Journal, 2004
- S100A1 Is a Novel Molecular Chaperone and a Member of the Hsp70/Hsp90 Multichaperone ComplexJournal of Biological Chemistry, 2004